Single-center, Open-label, Randomized, Multiple-dose, Parallel-group Study to Investigate Safety and Effects on Heart Rate, Blood Pressure, and Pharmacokinetic Interactions of ACT-334441 Combined With Calcium-channel Blocker (Diltiazem) or Beta-blocker (Atenolol) Treatment in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 28 Jul 2017
At a glance
- Drugs Cenerimod (Primary) ; Atenolol; Diltiazem
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Actelion Pharmaceuticals
- 09 Jun 2016 Status changed from suspended to discontinued.
- 12 Aug 2015 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
- 27 Jun 2015 New trial record